Efficacy with vimseltinib in patients with tenosynovial giant cell tumor and prior colony-stimulating factor 1 inhibitor therapy: a phase 2 case series
Effect of a high-fat meal on the pharmacokinetics of vimseltinib, an oral inhibitor of the colony-stimulating factor 1 receptor, in healthy participants
Health-related Quality of Life Measured by EQ-5D Utility Scores among Patients with TGCT: A Trial-based Analysis of EQ-5D Data from Patients in the MOTION Trial
Long-term efficacy and safety of vimseltinib in patients with tenosynovial giant cell tumor: 2-year results from the MOTION phase 3 trial
The economic and humanistic burden of tenosynovial giant cell tumor: a targeted literature review
Long-term clinical outcome assessments in patients with tenosynovial giant cell tumor treated with vimseltinib: 1-year results from the MOTION phase 3 trial
Characterizing Improvements in Physical Functioning with PROMIS-PF and In-trial Exit Interviews: A Mixed-methods Analysis to Understand the Meaningful Changes Experienced by Patients on Vimseltinib in the MOTION Trial
The Burden of Surgery for Tenosynovial Giant Cell Tumor: A Targeted Review
A Mixed-Methods Analysis to Define Minimum Clinically Importance Differences (MCIDs) in Range of Motion, Physical Function, and Worst Stiffness in Patients with Tenosynovial Giant Cell Tumor (TGCT)
Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial
